AAPL327.47+5.81 (+1.81%) ▲|ABBV259.24+2.32 (+0.90%) ▲|ABT102.42+1.67 (+1.66%) ▲|ACN144.04+5.30 (+3.82%) ▲|ADBE219.40+7.23 (+3.41%) ▲|AMAT547.41-15.40 (-2.74%) ▼|AMD524.18-15.51 (-2.87%) ▼|AMGN376.75+5.25 (+1.41%) ▲|AMT169.27+4.62 (+2.80%) ▲|AMZN232.83-0.84 (-0.36%) ▼|AVGO382.28-10.19 (-2.60%) ▼|AXP321.64-19.21 (-5.63%) ▼|BA209.29+0.06 (+0.03%) ▲|BAC61.83+0.55 (+0.90%) ▲|BKNG175.37+2.54 (+1.47%) ▲|BLK1,040.77+3.61 (+0.35%) ▲|BMY62.21+0.70 (+1.14%) ▲|BNY159.46-0.66 (-0.41%) ▼|BRK-B492.57+1.72 (+0.35%) ▲|C132.69+0.81 (+0.61%) ▲|CAT896.48+1.94 (+0.22%) ▲|CL90.86+0.78 (+0.86%) ▲|CMCSA22.28+0.36 (+1.64%) ▲|COF200.25+0.29 (+0.14%) ▲|COP120.68+0.48 (+0.40%) ▲|COST929.68+3.62 (+0.39%) ▲|CRM161.23+4.30 (+2.74%) ▲|CSCO112.76-0.01 (0.00%) ▼|CVS107.83+0.94 (+0.88%) ▲|CVX194.68+0.26 (+0.13%) ▲|DE613.86+3.84 (+0.63%) ▲|DHR192.21-0.29 (-0.15%) ▼|DIS94.57+1.74 (+1.87%) ▲|DUK130.10+0.84 (+0.65%) ▲|EMR147.10+2.20 (+1.52%) ▲|FDX316.56+0.94 (+0.30%) ▲|GD386.17+4.38 (+1.15%) ▲|GE356.21+7.21 (+2.06%) ▲|GEV1,020.28-10.91 (-1.06%) ▼|GILD129.86-1.01 (-0.77%) ▼|GM82.69+2.02 (+2.50%) ▲|GOOG322.10+3.76 (+1.18%) ▲|GOOGL322.24+4.55 (+1.43%) ▲|GS1,069.88-4.84 (-0.45%) ▼|HD325.84+1.13 (+0.35%) ▲|HON243.71-2.56 (-1.04%) ▼|IBM211.32+4.67 (+2.26%) ▲|INTC96.19-4.04 (-4.03%) ▼|INTU290.04+8.51 (+3.02%) ▲|ISRG335.65+3.63 (+1.09%) ▲|JNJ261.61+2.34 (+0.90%) ▲|JPM350.56+0.66 (+0.19%) ▲|KO81.40+0.23 (+0.28%) ▲|LIN509.87+3.55 (+0.70%) ▲|LLY1,197.81+11.94 (+1.01%) ▲|LMT580.77+12.18 (+2.14%) ▲|LOW204.11+2.19 (+1.08%) ▲|LRCX311.77-8.01 (-2.50%) ▼|MA534.88+4.59 (+0.87%) ▲|MCD264.06+1.26 (+0.48%) ▲|MDLZ59.99-0.06 (-0.10%) ▼|MDT82.78+0.77 (+0.94%) ▲|META604.36-1.74 (-0.29%) ▼|MMM170.75+1.16 (+0.68%) ▲|MO72.73+0.65 (+0.90%) ▲|MRK130.24-0.24 (-0.18%) ▼|MS214.04-1.14 (-0.53%) ▼|MSFT381.95+0.37 (+0.10%) ▲|MU929.06-61.16 (-6.18%) ▼|NEE88.94-0.85 (-0.95%) ▼|NFLX69.20+0.31 (+0.45%) ▲|NKE41.00+0.01 (+0.02%) ▲|NOW95.93+3.99 (+4.34%) ▲|NVDA207.41-1.35 (-0.65%) ▼|ORCL117.31-2.73 (-2.27%) ▼|PEP134.99+0.04 (+0.03%) ▲|PFE24.55-0.04 (-0.14%) ▼|PG147.08+1.20 (+0.82%) ▲|PLTR122.85-0.52 (-0.42%) ▼|PM193.77+2.65 (+1.39%) ▲|QCOM167.40-3.71 (-2.17%) ▼|RTX211.72+2.56 (+1.22%) ▲|SBUX104.47+1.26 (+1.22%) ▲|SCHW101.77+0.16 (+0.15%) ▲|SO97.50+0.90 (+0.93%) ▲|SPG227.65+2.45 (+1.09%) ▲|T23.61+0.65 (+2.83%) ▲|TMO562.62-9.70 (-1.69%) ▼|TMUS177.36+6.94 (+4.07%) ▲|TSLA315.64-4.05 (-1.27%) ▼|TXN279.89-5.10 (-1.79%) ▼|UBER68.75-0.17 (-0.24%) ▼|UNH423.17-0.39 (-0.09%) ▼|UNP303.11-1.22 (-0.40%) ▼|UPS114.05-0.05 (-0.04%) ▼|USB63.65+0.32 (+0.51%) ▲|V353.23+1.63 (+0.46%) ▲|VZ45.06+1.24 (+2.82%) ▲|WFC86.24+0.05 (+0.06%) ▲|WMT108.88+0.48 (+0.44%) ▲|XOM157.22+0.33 (+0.21%) ▲|AAPL327.47+5.81 (+1.81%) ▲|ABBV259.24+2.32 (+0.90%) ▲|ABT102.42+1.67 (+1.66%) ▲|ACN144.04+5.30 (+3.82%) ▲|ADBE219.40+7.23 (+3.41%) ▲|AMAT547.41-15.40 (-2.74%) ▼|AMD524.18-15.51 (-2.87%) ▼|AMGN376.75+5.25 (+1.41%) ▲|AMT169.27+4.62 (+2.80%) ▲|AMZN232.83-0.84 (-0.36%) ▼|AVGO382.28-10.19 (-2.60%) ▼|AXP321.64-19.21 (-5.63%) ▼|BA209.29+0.06 (+0.03%) ▲|BAC61.83+0.55 (+0.90%) ▲|BKNG175.37+2.54 (+1.47%) ▲|BLK1,040.77+3.61 (+0.35%) ▲|BMY62.21+0.70 (+1.14%) ▲|BNY159.46-0.66 (-0.41%) ▼|BRK-B492.57+1.72 (+0.35%) ▲|C132.69+0.81 (+0.61%) ▲|CAT896.48+1.94 (+0.22%) ▲|CL90.86+0.78 (+0.86%) ▲|CMCSA22.28+0.36 (+1.64%) ▲|COF200.25+0.29 (+0.14%) ▲|COP120.68+0.48 (+0.40%) ▲|COST929.68+3.62 (+0.39%) ▲|CRM161.23+4.30 (+2.74%) ▲|CSCO112.76-0.01 (0.00%) ▼|CVS107.83+0.94 (+0.88%) ▲|CVX194.68+0.26 (+0.13%) ▲|DE613.86+3.84 (+0.63%) ▲|DHR192.21-0.29 (-0.15%) ▼|DIS94.57+1.74 (+1.87%) ▲|DUK130.10+0.84 (+0.65%) ▲|EMR147.10+2.20 (+1.52%) ▲|FDX316.56+0.94 (+0.30%) ▲|GD386.17+4.38 (+1.15%) ▲|GE356.21+7.21 (+2.06%) ▲|GEV1,020.28-10.91 (-1.06%) ▼|GILD129.86-1.01 (-0.77%) ▼|GM82.69+2.02 (+2.50%) ▲|GOOG322.10+3.76 (+1.18%) ▲|GOOGL322.24+4.55 (+1.43%) ▲|GS1,069.88-4.84 (-0.45%) ▼|HD325.84+1.13 (+0.35%) ▲|HON243.71-2.56 (-1.04%) ▼|IBM211.32+4.67 (+2.26%) ▲|INTC96.19-4.04 (-4.03%) ▼|INTU290.04+8.51 (+3.02%) ▲|ISRG335.65+3.63 (+1.09%) ▲|JNJ261.61+2.34 (+0.90%) ▲|JPM350.56+0.66 (+0.19%) ▲|KO81.40+0.23 (+0.28%) ▲|LIN509.87+3.55 (+0.70%) ▲|LLY1,197.81+11.94 (+1.01%) ▲|LMT580.77+12.18 (+2.14%) ▲|LOW204.11+2.19 (+1.08%) ▲|LRCX311.77-8.01 (-2.50%) ▼|MA534.88+4.59 (+0.87%) ▲|MCD264.06+1.26 (+0.48%) ▲|MDLZ59.99-0.06 (-0.10%) ▼|MDT82.78+0.77 (+0.94%) ▲|META604.36-1.74 (-0.29%) ▼|MMM170.75+1.16 (+0.68%) ▲|MO72.73+0.65 (+0.90%) ▲|MRK130.24-0.24 (-0.18%) ▼|MS214.04-1.14 (-0.53%) ▼|MSFT381.95+0.37 (+0.10%) ▲|MU929.06-61.16 (-6.18%) ▼|NEE88.94-0.85 (-0.95%) ▼|NFLX69.20+0.31 (+0.45%) ▲|NKE41.00+0.01 (+0.02%) ▲|NOW95.93+3.99 (+4.34%) ▲|NVDA207.41-1.35 (-0.65%) ▼|ORCL117.31-2.73 (-2.27%) ▼|PEP134.99+0.04 (+0.03%) ▲|PFE24.55-0.04 (-0.14%) ▼|PG147.08+1.20 (+0.82%) ▲|PLTR122.85-0.52 (-0.42%) ▼|PM193.77+2.65 (+1.39%) ▲|QCOM167.40-3.71 (-2.17%) ▼|RTX211.72+2.56 (+1.22%) ▲|SBUX104.47+1.26 (+1.22%) ▲|SCHW101.77+0.16 (+0.15%) ▲|SO97.50+0.90 (+0.93%) ▲|SPG227.65+2.45 (+1.09%) ▲|T23.61+0.65 (+2.83%) ▲|TMO562.62-9.70 (-1.69%) ▼|TMUS177.36+6.94 (+4.07%) ▲|TSLA315.64-4.05 (-1.27%) ▼|TXN279.89-5.10 (-1.79%) ▼|UBER68.75-0.17 (-0.24%) ▼|UNH423.17-0.39 (-0.09%) ▼|UNP303.11-1.22 (-0.40%) ▼|UPS114.05-0.05 (-0.04%) ▼|USB63.65+0.32 (+0.51%) ▲|V353.23+1.63 (+0.46%) ▲|VZ45.06+1.24 (+2.82%) ▲|WFC86.24+0.05 (+0.06%) ▲|WMT108.88+0.48 (+0.44%) ▲|XOM157.22+0.33 (+0.21%) ▲|
21.4 C
New York
Friday, July 24, 2026

Tag: malignancies

newssourceFORcompanyinformationcontent1releasesmarket

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Registration Opens for JADPRO Live 2026: Advanced Practitioners Gather in the Heartland to Champion High-Quality Cancer Care

The annual JADPRO Live conference for oncology advanced practitioners will take place this year from October 15 through 18 at the Minneapolis Convention Center...

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

Allegheny Health Network’s Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types

Systemwide research initiative uses blood‑based genomics to improve early detection and personalize cancer treatmentPITTSBURGH, June 12, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) Cancer...

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMalignancies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers